Skip to content

Single Crown Supported by Short Implant Versus Standard Implant in Conjunction With Maxillary Sinus Floor Augmentation.

Single Crown Supported by Short Implant Versus Standard Implant in Conjunction With Maxillary Sinus Floor Augmentation in the Posterior: a Randomized, Controlled Clinical Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04518020
Enrollment
40
Registered
2020-08-19
Start date
2016-11-16
Completion date
2025-07-01
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implant Failed

Brief summary

Implant placement in the posterior part of the maxilla is frequently compromised due to atrophy of the alveolar process. Therefore, alveolar ridge augmentation is frequently necessary before or in conjunction with implant placement. The most commonly used method to augment the maxillary premolar and molar region involves the maxillary sinus floor augmentation (MSFA) with autogenous bone graft or a bone substitute. However, the use of autogenous bone grafts is associated with risk at the donor site morbidity and unpredictable graft resorption. Consequently, short implants are used increasingly to eliminate the need for bone augmentation. However, long-term studies comparing short implants and standard implants in conjunction with MSFA supporting single crown restoration in the posterior maxilla are missing. The primary outcome measures include survival of implant and suprastructures, peri-implant marginal bone level (MBL), professional evaluation of the suprastructure and soft tissue using pink esthetic score (PES) and white esthetic score (WES), patient satisfaction using visual analogue scale (VAS), and oral health related quality of life using oral health impact profile (OHIP-14) questionnaire. Secondary outcome measure include evaluation of the complication rate related to the two treatment modalities.

Detailed description

The primary objective of the present study is to test the H0 hypothesis of: 1. No differences in survival of suprastructures and implants with the two treatment modalities. 2. No differences in peri-implant MBL, PES, WES, and patient satisfaction using VAS with the two treat modalities. 3. No differences in oral health related quality of life using OHIP-14 with the two treatment modalities. The secondary objective will include: 1\. Complications related to bone harvesting, implant installation, and MSFA. The primary outcome measures included: * Survival of suprastructures. * Survival of implants. * Radiographic peri-implant MBL. * Professional evaluation of suprastructure and soft tissue using PES and WES. * Patient satisfaction using VAS * Oral health related quality of life using OHIP-14 questionnaire. Secondary outcome measures: • Pre- and postoperative complications.

Interventions

PROCEDURE40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA

40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).

Sponsors

Dentsply International
CollaboratorINDUSTRY
Aalborg University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized controlled clinical trial (RCT)

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* \>20 years * Partial edentulism in the posterior maxilla. * Height and weight of the maxillary alveolar process of at least 5.5 mm. * Mandibular occluding teeth.

Exclusion criteria

* General contraindications to implant therapy. * Poor oral hygiene. * Progressive periodontitis. * Acute infection in the area intended for implant placement. * Parafunction, bruxism, or clenching. * Psychiatric problems or unrealistic expectations. * Heavy tobacco use, define as \>10 cigarettes per day. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Radiographic MBL.1-year follow upMeasurement of marginal bone level in millimeter.
Survival of suprastructures.1-year follow upSurvival of suprastructures is defined as absence of mechanical/or biological complications causing loss of suprastructures. Chipping of ceramics and loosening of the suprastructure were not categorized as loss of suprastructure.
Survival of implants.1-year follow upSurvival of implants is defined as clinically stable and osseointegrated implants with absence of mobility, progressive marginal bone loss, and infection.
Oral health related quality of life as defined by oral health impact profile (OHIP-14).1-year follow upEvaluation of oral health related quality of life using OHIP-14 questionnaire. OHIP-14 scale ranges from 0 to 56, with higher scores indicating poorer oral health impact profile.
Professional evaluation of the prosthetic restoration and soft tissue using pink esthetic score (PES) and white esthetic score (WES).1-year follow upEsthetic evaluation of suprastructure and soft tissue using PES and WES. PES includes 7 different variables: mesial papilla, distal papilla, soft-tissue level, soft-tissue contour, alveolar process deficiency, soft-tissue colour, and texture. Each variable is assessed with a 0, 1, or 2 score, with 0 being the poorest score and 2 the best according to the degree of match or mismatch compared with the anterior premolar or molar. The highest possible PES is 14. WES includes 5 different variables: Crown form, volume, colour, translucency, and texture. Each variable is assessed with a 0, 1, or 2 score, with 0 being the poorest score and 2 the best according to the degree of match or mismatch compared with the anterior premolar or molar. The highest possible WES is 10.
Patient satisfaction.1-year follow upEvaluation of patient satisfaction using visual analogue scale (VAS). VAS with 0 indicating extreme dissatisfaction and 10 indicating complete satisfaction.

Secondary

MeasureTime frameDescription
Complications.1-year follow upEvaluation of biological and mechanical complication rate.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026